Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Aged
Antibodies, Monoclonal, Humanized
/ pharmacology
Betacoronavirus
Biological Factors
/ pharmacology
Biological Therapy
/ methods
COVID-19
Cohort Studies
Coronavirus Infections
/ complications
Female
Humans
Interleukin-17
/ antagonists & inhibitors
Italy
Pandemics
Pneumonia, Viral
/ complications
Psoriasis
/ complications
SARS-CoV-2
Severity of Illness Index
Treatment Outcome
Anti-IL-17
Covid-19
coronavirus
psoriasis
secukinumab
Journal
Expert opinion on biological therapy
ISSN: 1744-7682
Titre abrégé: Expert Opin Biol Ther
Pays: England
ID NLM: 101125414
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
9
6
2020
medline:
11
8
2020
entrez:
9
6
2020
Statut:
ppublish
Résumé
In light of the current Covid-19 pandemic and the ongoing, extensive debate about the use of biological agents in psoriatic patients, we felt compelled to relate our experience in the use of secukinumab in the same cohort before and during the lockdown in Italy.
Identifiants
pubmed: 32510244
doi: 10.1080/14712598.2020.1779217
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Factors
0
Interleukin-17
0
secukinumab
DLG4EML025
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM